Floatz logo

Recombinant Vesicular Stomatitis Virus-Expressing Interferon-Beta

Recurrent Angioimmunoblastic T-Cell Lymphoma

Mayo Clinicgene_therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

54 Active assets in the Recurrent Angioimmunoblastic T-Cell Lymphoma cohort.

Asset / SponsorPhaseRating
Ifosfamide
Shandong Provincial Hospital
Phase 4BBB
DEXAMETHASONE
Ou Bai, MD/PHD
Phase 2BB
ETOPOSIDE
Eric Jacobsen, MD
Phase 4BB
Fludarabine
National Cancer Institute (NCI)
Phase 2BB
Inno-206
City of Hope Medical Center
Phase 4BB

View all 50 →

Same molecule, other indications

Recombinant Vesicular Stomatitis Virus-Expressing Interferon-Beta is also rated in:

renal cell carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
nonpapillary renal cell carcinomaDormant
CCC
Indicative ·
53 / 100
View asset →
Advanced Malignant Solid NeoplasmDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →